S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies

被引：0
|
作者：
Nikolaus B Wagner
Andrea Forschner
Ulrike Leiter
Claus Garbe
Thomas K Eigentler
机构：
[1] University Hospital Tuebingen,Department of Dermatology
来源：
British Journal of Cancer | 2018年 / 119卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：339 / 346
页数：7
相关论文
共 50 条
  • [31] Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody
    Azuma, Takeshi
    Takeuchi, Takumi
    Matayoshi, Yukihide
    Namiki, Shin
    Obara, Tetsuya
    Imamura, Kazuhiro
    Takamori, Mikio
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [32] Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
    Gauci, Marie-Lea
    Boudou, Philippe
    Baroudjian, Barouyr
    Vidal-Trecan, Tiphaine
    Da Meda, Laetitia
    Madelaine-Chambrin, Isabelle
    Basset-Seguin, Nicole
    Bagot, Martine
    Pages, Cecile
    Mourah, Samia
    Resche-Rigon, Matthieu
    Pinel, Sylvine
    Sassier, Marion
    Rouby, Franck
    Eftekhari, Pirayeh
    Lebbe, Celeste
    Gautier, Jean-Francois
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (08) : 1197 - 1208
  • [33] Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody
    Takeshi Azuma
    Takumi Takeuchi
    Yukihide Matayoshi
    Shin Namiki
    Tetsuya Obara
    Kazuhiro Imamura
    Mikio Takamori
    Scientific Reports, 11
  • [34] Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
    Marie-Léa Gauci
    Philippe Boudou
    Barouyr Baroudjian
    Tiphaine Vidal-Trecan
    Laetitia Da Meda
    Isabelle Madelaine-Chambrin
    Nicole Basset-Seguin
    Martine Bagot
    Cécile Pages
    Samia Mourah
    Matthieu Resche-Rigon
    Sylvine Pinel
    Marion Sassier
    Franck Rouby
    Pirayeh Eftekhari
    Céleste Lebbé
    Jean-François Gautier
    Cancer Immunology, Immunotherapy, 2018, 67 : 1197 - 1208
  • [35] Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
    Seidel, Judith A.
    Otsuka, Atsushi
    Kabashima, Kenji
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [36] First-line anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy in Japanese mucosal melanoma: A retrospective, multicenter study (JMAC study)
    Nakamura, Y.
    Namikawa, K.
    Yoshikawa, S.
    Kiniwa, Y.
    Maekawa, T.
    Yamasaki, O.
    Isei, T.
    Matsushita, S.
    Nomura, M.
    Nakai, Y.
    Fukushima, S.
    Saito, S.
    Takenouchi, T.
    Tanaka, R.
    Kato, H.
    Otsuka, A.
    Matsuya, T.
    Baba, N.
    Nagase, K.
    Inozume, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S876 - S876
  • [37] Molecular signature of immune cells infiltrating tumors A key to predict the response to anti-PD-1 and anti-CTLA-4 antibodies
    Stanciu, Raluca
    Furge, Philippine
    M S-MEDECINE SCIENCES, 2019, 35 (04): : 382 - 382
  • [38] Distinct cellular mechanisms mediate anti-CTLA-4 and anti-PD-1 checkpoint blockade
    Wei, Spencer C.
    Levine, Jacob H.
    Pe'er, Dana
    Allison, James P.
    CANCER RESEARCH, 2017, 77
  • [39] Tumor eradication in a murine model of glioma with vaccination and anti-CTLA-4 but not anti-PD-1
    Field, Cameron S.
    Hunn, Martin K.
    Ferguson, Peter M.
    Yagita, Hideo
    Hermans, Ian F.
    Ancelet, Lindsay R.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [40] Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
    Wei, Spencer
    Levine, Jacob
    Cogdill, Alexandria
    Zhao, Yang
    Anang, Nana-Ama
    Andrews, Miles
    Sharma, Padmanee
    Wang, Jing
    Wargo, Jennifer
    Pe'er, Dana
    Allison, James
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
12345